Status and phase
Conditions
Treatments
About
The aim of the study is to determine whether switching from an antiretroviral regimen containing abacavir and/or didanosine to one containing maraviroc will lead to a reduction in platelet reactivity and inflammatory markers at weeks 12 and 24 thereby conferring a reduction in cardiac risk.
In addition the study will assess the efficacy of a maraviroc containing regimen in combination with a boosted protease inhibitor in terms of tolerability and achieving long term viral suppression as assessed at week 48.
The investigators hypothesize that there will be a rapid reduction in platelet reactivity on switching to maraviroc and that a boosted protease inhibitor in combination with maraviroc will provide a safe and efficacious antiretroviral regimen enabling a reduction in cardiac risk whilst maintaining virological suppression.
Full description
To assess the safety, changes in platelet reactivity, plasma cardiac biomarkers and metabolic parameters in HIV 1 infected subjects undergoing a switch in ART from a nucleoside containing regimen which includes abacavir and / or didanosine to a maraviroc containing regimen.
40 HIV-1 infected subjects currently receiving stable antiretroviral therapy consisting of a boosted protease inhibitor and two NRTIs including abacavir and / or didanosine will be recruited. Subjects will be randomized on a 1:1 basis to one of two arms:
Arm 1 (immediate switch in antiretroviral therapy)
Arm 2 (continue current antiretroviral therapy)
Subjects will be followed up for 48 weeks and will attend for clinic visits at screening, baseline, weeks 4, 12, 16, 24, 36 and 48. Platelet reactivity, inflammatory and cardiac biomarkers and markers of T cell activation will be assessed at baseline, week 12 and week 24.
Following completion of the study subjects may continue their study antiretroviral regimen or switch to an alternative regimen at their clinician's discretion.
Inclusion Criteria
HIV-1 infected males or females
Between 18 and 65 years of age
Signed informed consent
Currently receiving a stable antiretroviral regimen comprising of:
Undetectable plasma HIV RNA to less than 50 copies/mL for at least 24 weeks prior to screening
Availability of stored plasma with which to perform a tropism assay
CCR5 tropic HIV virus based on a tropism assay from a stored plasma sample
Willing to continue unchanged, or to modify antiretroviral therapy, in accordance with the randomisation assignment
No documented viral resistance to currently licensed HIV-1 protease inhibitors based either on previous HIV-1 genotypic resistance testing or in the judgement of the study investigators
No previous exposure to maraviroc or CCR5 receptor antagonists
Subjects in good health upon medical history, physical exam, and laboratory testing in the opinion of the investigator
Female subjects who are heterosexually active and of childbearing potential (i.e., not surgically sterile or at least two years post menopausal) must avoid becoming pregnancy as follows from screening through completion of the study using one or both of the following methods:
Female subjects of childbearing potential must have a negative pregnancy test. Exclusion criteria
failure of current antiretroviral regimen due to virological failure
active opportunistic infection, malignancy or significant co-morbidities in the opinion of the investigator
pregnancy
current prohibited concomitant medication (as listed in section 4.1.4)
no available stored plasma sample predating their current antiretroviral regimen upon which a tropism assay can be performed
active HBV infection as evidenced by positive hepatitis B surface antigen
active hepatitis C virus infection as evidenced by positive HCV PCR or HCV antibody
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
HIV-1 infected males or females
Between 18 and 65 years of age
Signed informed consent
Currently receiving a stable antiretroviral regimen comprising of:
Undetectable plasma HIV RNA to less than 50 copies/mL for at least 24 weeks prior to screening
Availability of stored plasma with which to perform a tropism assay
CCR5 tropic HIV virus based on a tropism assay from a stored plasma sample
Willing to continue unchanged, or to modify antiretroviral therapy, in accordance with the randomisation assignment
No documented viral resistance to currently licensed HIV-1 protease inhibitors based either on previous HIV-1 genotypic resistance testing or in the judgement of the study investigators
No previous exposure to maraviroc or CCR5 receptor antagonists
Subjects in good health upon medical history, physical exam, and laboratory testing in the opinion of the investigator
Female subjects who are heterosexually active and of childbearing potential (i.e., not surgically sterile or at least two years post menopausal) must avoid becoming pregnancy as follows from screening through completion of the study using one or both of the following methods:
Female subjects of childbearing potential must have a negative pregnancy test
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
18 participants in 2 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal